GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharos IBio Co Ltd (XKRX:388870) » Definitions » Beneish M-Score

Pharos IBio Co (XKRX:388870) Beneish M-Score : 0.00 (As of Mar. 02, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Pharos IBio Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Pharos IBio Co's Beneish M-Score or its related term are showing as below:

During the past 5 years, the highest Beneish M-Score of Pharos IBio Co was 0.00. The lowest was 0.00. And the median was 0.00.


Pharos IBio Co Beneish M-Score Historical Data

The historical data trend for Pharos IBio Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharos IBio Co Beneish M-Score Chart

Pharos IBio Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - -6.32 - -

Pharos IBio Co Quarterly Data
Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pharos IBio Co's Beneish M-Score

For the Biotechnology subindustry, Pharos IBio Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharos IBio Co's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharos IBio Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Pharos IBio Co's Beneish M-Score falls into.



Pharos IBio Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Pharos IBio Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was ₩157.26 Mil.
Revenue was 0 + 0 + 0 + 0 = ₩0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = ₩0.00 Mil.
Total Current Assets was ₩17,813.13 Mil.
Total Assets was ₩21,016.56 Mil.
Property, Plant and Equipment(Net PPE) was ₩2,970.72 Mil.
Depreciation, Depletion and Amortization(DDA) was ₩784.54 Mil.
Selling, General, & Admin. Expense(SGA) was ₩1,179.56 Mil.
Total Current Liabilities was ₩607.45 Mil.
Long-Term Debt & Capital Lease Obligation was ₩48.78 Mil.
Net Income was -2537.571 + -2844.126 + -3004.999 + -2326.338 = ₩-10,713.03 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ₩0.00 Mil.
Cash Flow from Operations was -1765.612 + -2680.179 + -3319.875 + -821.887 = ₩-8,587.55 Mil.
Total Receivables was ₩290.15 Mil.
Revenue was 0 + 0 + 0 + 0 = ₩0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = ₩0.00 Mil.
Total Current Assets was ₩28,537.22 Mil.
Total Assets was ₩31,860.74 Mil.
Property, Plant and Equipment(Net PPE) was ₩2,977.57 Mil.
Depreciation, Depletion and Amortization(DDA) was ₩641.16 Mil.
Selling, General, & Admin. Expense(SGA) was ₩1,141.90 Mil.
Total Current Liabilities was ₩1,070.73 Mil.
Long-Term Debt & Capital Lease Obligation was ₩172.49 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(157.26 / 0) / (290.146 / 0)
= /
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0 / 0) / (0 / 0)
= /
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (17813.125 + 2970.717) / 21016.561) / (1 - (28537.219 + 2977.57) / 31860.738)
=0.011073 / 0.010858
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0 / 0
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(641.162 / (641.162 + 2977.57)) / (784.538 / (784.538 + 2970.717))
=0.177179 / 0.208917
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1179.559 / 0) / (1141.903 / 0)
= /
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((48.779 + 607.45) / 21016.561) / ((172.485 + 1070.734) / 31860.738)
=0.031224 / 0.03902
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-10713.034 - 0 - -8587.553) / 21016.561
=-0.101134

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.


Pharos IBio Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Pharos IBio Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharos IBio Co Business Description

Traded in Other Exchanges
N/A
Address
427beon-gil, Dongan-gu, 1407 and 1408, 38, Heungan-daero, Seongji Star With, Gyeonggi-do, Gwanyang-dong, Anyang-si, KOR
Pharos IBio Co Ltd is a company specializing in new drug development that develops treatments for rare and intractable diseases. It utilizes a new drug development platform based on big data and AI technology. Its product candidate comprises PHI-101-AML, a treatment drug for refractory/relapsed acute myeloid leukemia; PHI-101-OC developed for platinum-resistant/refractory ovarian cancer patients; PHI-101-TNBC is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC); PHI-201; PHI-301; and PHI-501.

Pharos IBio Co Headlines

No Headlines